The Clinical Significance of Serum IL-33 and sST2 Alterations in the Post-Stroke Depression

References

• Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry. 2016;173:221–231. doi:10.1176/appi.ajp.2015.15030363
   PubMed Web of Science ®Google Scholar
• Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131–144. doi:10.1016/j.pharmthera.2017.11.005
   PubMed Web of Science ®Google Scholar
• Cai W, Mueller C, Li YJ, Shen WD, Stewart R. Post stroke depression and risk of stroke recurrence and mortality: a systematic review and meta-analysis. Ageing Res Rev. 2019;50:102–109. doi:10.1016/j.arr.2019.01.013
   PubMed Web of Science ®Google Scholar
• Guiraud V, Gallarda T, Calvet D, et al. Depression predictors within six months of ischemic stroke: the DEPRESS study. Int J Stroke. 2016;11:519–525. doi:10.1177/1747493016632257
   Web of Science ®Google Scholar
• Kouwenhoven SE, Kirkevold M, Engedal K, Kim HS. Depression in acute stroke: prevalence, dominant symptoms and associated factors. Disabil Rehabil. 2011;33:539–556. doi:10.3109/09638288.2010.505997
   PubMed Web of Science ®Google Scholar
• Naghavi FS, Koffman EE, Lin B, Du J. Post-stroke neuronal circuits and mental illnesses. Int J Physiol Pathophysiol Pharmacol. 2019;11:1–11.
   Google Scholar
• Zhang XF, Zou W, Yang Y. Effects of IL-6 and cortisol fluctuations in post-stroke depression. J Huazhong Univ Sci Technolog Med Sci. 2016;36(5):732–735. doi:10.1007/s11596-016-1653-0
   Google Scholar
• Kang HJ, Bae KY, Kim SW, et al. Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up. Psychoneuroendocrinology. 2016;72:156–160. doi:10.1016/j.psyneuen.2016.07.001
   PubMed Web of Science ®Google Scholar
• Vocca L, Di Sano C, Uasuf CG, et al. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. 2015;220:954–963. doi:10.1016/j.imbio.2015.02.005
   PubMed Web of Science ®Google Scholar
• Yang J, Huang X, Hu F, Fu X, Jiang Z, Chen K. LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2. Cell Cycle. 2019;18:3393–3403. doi:10.1080/15384101.2019.1678965
   PubMed Web of Science ®Google Scholar
• Du LX, Wang YQ, Hua GQ, Mi WL. IL-33/ST2 pathway as a rational therapeutic target for CNS diseases. Neuroscience. 2018;369:222–230. doi:10.1016/j.neuroscience.2017.11.028
   PubMed Web of Science ®Google Scholar
• Xu WD, Zhang M, Zhang YJ, Ye DQ. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. Hum Immunol. 2013;74:1057–1060. doi:10.1016/j.humimm.2013.06.029
   PubMed Web of Science ®Google Scholar
• Li XM, Wang XY, Feng XW, et al. Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients. Brain Behav. 2019;9:e01369. doi:10.1002/brb3.1369
   Web of Science ®Google Scholar
• Xiao W, Guo S, Chen L, Luo Y. The role of Interleukin-33 in the modulation of splenic T-cell immune responses after experimental ischemic stroke. J Neuroimmunol. 2019;333:576970. doi:10.1016/j.jneuroim.2019.576970
   Web of Science ®Google Scholar
• Li P, Zhang QL, Li SY. [The relationship between acute inflammatory cytokines, nerve function defect, daily living ability and PSD]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2017;33:121–123. doi:10.12047/j.cjap.5512.2017.031. Chinese
   Google Scholar
• Cheng LS, Tu WJ, Shen Y, Zhang LJ, Ji K. Combination of high-sensitivity C-reactive protein and homocysteine predicts the post-stroke depression in patients with ischemic stroke. Mol Neurobiol. 2018;55:2952–2958. doi:10.1007/s12035-017-0549-8
   PubMed Web of Science ®Google Scholar
• Mu Y, Wang Z, Zhou J, Tan C, Wang H. Correlations of post-stroke depression with inflammatory response factors. Iran J Public Health. 2018;7:988–993.
   Google Scholar
• Yang RR, Lu BC, Li T, Du YF, Wang X, Jia YX. The relationship between high-sensitivity C-reactive protein at admission and post stroke depression: a 6-month follow-up study. Int J Geriatr Psychiatry. 2016;31:231–239. doi:10.1002/gps.4315
   PubMed Web of Science ®Google Scholar
• McCarthy PC, Phair IR, Greger C, et al. IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3. Immunol Cell Biol. 2019;97(1):54–71. doi:10.1111/imcb.12200
   PubMed Web of Science ®Google Scholar
• Bawazeer MA, Theoharides TC. IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Eur J Pharmacol. 2019;865:172760. doi:10.1016/j.ejphar.2019.172760
   PubMed Web of Science ®Google Scholar
• Ali S, Mohs A, Thomas M, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 2011;187:1609–1616. doi:10.4049/jimmunol.1003080
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou Y, Xiao W, et al. Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res. 2015;1597:86–94. doi:10.1016/j.brainres.2014.12.005
   PubMed Web of Science ®Google Scholar
• Zhang SR, Piepke M, Chu HX, et al. IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke. JCI Insight. 2018;3(18):e121560. doi:10.1172/jci.insight.121560
   Web of Science ®Google Scholar
• Li Q, Lin Y, Huang W, et al. Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke. Aging Dis. 2016;7:614–622. doi:10.14336/AD.2016.0207
   Web of Science ®Google Scholar
• Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A. Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol. 2013;8:643–650. doi:10.1007/s11481-013-9439-7
   Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245–254. doi:10.1016/S0140-6736(13)61953-4
   PubMed Web of Science ®Google Scholar
• Keck F, Kortchak S, Bakovic A, Roberts B, Agrawal N, Narayanan A. Direct and indirect pro-inflammatory cytokine response resulting from TC-83 infection of glial cells. Virulence. 2018;9:1403–1421. doi:10.1080/21505594.2018.1509668
   PubMed Web of Science ®Google Scholar
• Reverchon F, Mortaud S, Sivoyon M, et al. IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS Pathog. 2017;13(4):e1006322. doi:10.1371/journal.ppat.1006322
   PubMed Web of Science ®Google Scholar
• Liang CS, Su KP, Tsai CL, et al. The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020;12:86. doi:10.1186/s13195-020-00652-z
   Web of Science ®Google Scholar
• Liu X, Xiao Y, Pan Y, Li H, Zheng SG, Su W. The role of the IL-33/ST2 axis in autoimmune disorders: friend or foe? Cytokine Growth Factor Rev. 2019;50:60–74. doi:10.1016/j.cytogfr.2019.04.004
   PubMed Web of Science ®Google Scholar
• Besnard AG, Guabiraba R, Niedbala W, et al. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog. 2015;11:e1004607. doi:10.1371/journal.ppat.1004607
   Web of Science ®Google Scholar
• Liew FY, Girard J-P, Turnquist HR, et al. Interleukin 33 in health and disease. Nat Rev Immunol. 2016;16:676–689. doi:10.1038/nri.2016.95
   PubMed Web of Science ®Google Scholar
• Nagy E, Frigy A, Szász JA, Horváth E. Neuroinflammation and microglia/macrophage phenotype modulate the molecular background of post-stroke depression: a literature review. Exp Therap Med. 2020;20:2510–2523.
   Web of Science ®Google Scholar